Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestogen presented as a 52 mg intrauterine system for intrauterine use. It prevents pregnancy by providing continuous hormonal contraception for up to five years.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert, a levonorgestrel‑based intrauterine system, is indicated for hormonal contraception.

- Contraception: provides up to five years of highly effective pregnancy prevention. - Heavy menstrual bleeding: reduces menstrual blood loss and improves bleeding patterns. - Endometrial protection in estrogen therapy: induces endometrial atrophy to lower bleeding risk.

Levosert may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or spotting. - Amenorrhea (absence of periods). - Pelvic or uterine cramping. - Breast tenderness or enlargement. - Acne or skin changes. - Mood swings or headache.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Pelvic inflammatory infection. - Expulsion of the device. - Ectopic pregnancy if contraception fails. - Ovarian cyst formation or rupture. - Severe allergic reaction to device components.

Before prescribing Levosert, clinicians should assess patient suitability and counsel on potential risks.

- Confirm uterine cavity size: ensure appropriate fit of the intrauterine system. - Exclude current pregnancy: verify negative pregnancy test before insertion. - Avoid in active pelvic infection: postpone insertion until infection resolves. - Counsel on bleeding pattern changes: inform patients that irregular bleeding is common initially. - Review thromboembolic risk: consider medical history of clotting disorders. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levosert may interact with other medicines that affect hormone metabolism or efficacy.

Major Interactions (Avoid): - Rifampicin and other enzyme inducers: may reduce levonorgestrel levels, decreasing contraceptive effectiveness. - Anticonvulsants such as phenytoin, carbamazepine, or phenobarbital: can lower hormone concentrations. - Efavirenz (HIV antiretroviral): may diminish contraceptive protection.

Moderate Interactions (Monitor Closely): - Ketoconazole and other strong antifungals: may increase levonorgestrel exposure, requiring monitoring for side effects. - St. John's wort: may modestly reduce hormone levels, warranting additional contraceptive measures.